33.59
-0.49 (-1.45%)
| Previous Close | 34.08 |
| Open | 33.75 |
| Volume | 32,554 |
| Avg. Volume (3M) | 595,958 |
| Market Cap | 1,710,537,728 |
| Price / Earnings (TTM) | 104.95 |
| Price / Earnings (Forward) | 76.92 |
| Price / Sales | 6.45 |
| Price / Book | 4.90 |
| 52 Weeks Range | |
| Earnings Date | 7 May 2026 |
| Profit Margin | 1.25% |
| Operating Margin (TTM) | -24.32% |
| Diluted EPS (TTM) | 0.050 |
| Quarterly Revenue Growth (YOY) | 2.60% |
| Quarterly Earnings Growth (YOY) | 52.40% |
| Total Debt/Equity (MRQ) | 33.72% |
| Current Ratio (MRQ) | 5.01 |
| Operating Cash Flow (TTM) | 57.56 M |
| Levered Free Cash Flow (TTM) | -22.77 M |
| Return on Assets (TTM) | -0.45% |
| Return on Equity (TTM) | 1.13% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Vericel Corporation | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 3.5 |
| Insider Activity | -1.5 |
| Price Volatility | 0.5 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | -2.0 |
| Average | -0.10 |
|
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company, specialized in various therapies for sports medicine and severe burn care markets. It markets two cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane) and Epicel (cultured epidermal autografts). The company operates in one reportable segment: the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 1.06% |
| % Held by Institutions | 107.99% |
| 52 Weeks Range | ||
| Median | 64.00 (90.56%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 27 Feb 2026 | 64.00 (90.56%) | Buy | 35.68 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| HOPPER JONATHAN MARK | - | 34.14 | -3,472 | -118,534 |
| RUBINO ALAN L | - | - | 0 | 0 |
| Aggregate Net Quantity | -3,472 | |||
| Aggregate Net Value ($) | -118,534 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 34.14 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| HOPPER JONATHAN MARK | Officer | 02 Apr 2026 | Automatic sell (-) | 3,472 | 34.14 | 118,534 |
| HOPPER JONATHAN MARK | Officer | 02 Apr 2026 | Option execute | 3,472 | - | - |
| RUBINO ALAN L | Director | 25 Mar 2026 | Option execute | 15,000 | - | - |
| Date | Type | Details |
|---|---|---|
| 13 Jan 2026 | Announcement | Vericel Announces Preliminary 2025 Financial Results and Business Updates |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |